MODIFIED PTO/SB/08 (08-00)

DET 1 6 2003

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

## Substitute for form 1449BXBTO EMS? INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 16, 2003

(use as many sheets as necessary) 1 of

Sheet

Complete If Known				
Application Number	09/783,580			
Filing Date	02/15/2001			
First Named Inventor	Lawrence E. CORNETT			
Group Art Unit	1632			
Examiner Name	Scott David Priebe			
Attorney Docket Number	023533-0113			

U.S. PATENT DOCUMENTS						
Cit		U.S. Patent D	Kind Code <sup>2</sup> (#	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
I NO	No. Nur	Number	Number Code <sup>2</sup> (if Cited Document known)	MM-DD-YYYY	_	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1		n Patent D Number <sup>4</sup>	kocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
								Г

		NON PATENT LITERATURE DOCUMENTS	_		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
50P A1		Chow et al., "Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgenic expression in lung airways, "Proc. Notl. Acad. Sci. USA, Vol. 94, pp. 14595-14700, December 1997 ©			
	A2	Chow et al., "Targeting Transgene Expression to Airway Epithelia and Submucosal Glands, Promient Sites of Human CFTR Expression," Molecular Therapy, Vol. 2, No. 4, October 2000, @ The American Society of Gene Therapy.			
	А3	Strayer et al., "Targeting Type II and Clara Cells for Adenovirus-mediated Gene Transfer Using the Surfactant Protein B Promoter," Am. J. Respir. Cell Mol. Biol., Vol. 18, pp. 1-11, 1998.			
	A4	Venhatesh et al., "Characterization of the promoter of human pulmonary surfactant protein B gene," Amer. J. Physiol., 268:L674-L682 (1995), @ American Physiological Society.			
=	A5	Weidenfeld et al., "The WNT7b Promoter is Regulated by TTF-1, GATA6, and Foxa2 in Lung Epithelium," The Journal of Biological Chemistry, Vol. 277, No. 23, pp. 21061-21070, June 7, 2002, ⊚ The American Society for Biochemistry and Molecular Biology, Inc.			
	A6	Foster et al., "Positive and Negative cis-Acting Regulatory Elements Mediate Expression of the Mouse Vascular Smooth Muscle cr-Actin Gene," The Journal of Biological Chemistry, Vol. 267, No. 17, pp. 11995- 12003, June 15, 1992, © The American Society for Blochemistry and Molecular Biology, Inc.			
1	Α7	Aluti, et al., "Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning," Science, Vol. 296, pp. 2410-2413, June 28, 2002.			
√ A8		Stripp et al., "cis-Acting Elements That Confer Lung Epithelial Cell Expression of the CC <sub>10</sub> Gene," The Journal of Biological Chemistry, Vol. 207, No. 21, pp. 14703-14712, July 1992, ©The Amercian Society for Biochemistry and Molecular Biology, Inc.			

Examiner Signature	Sist D. Priche	Date Considered	12/15/03
	<del></del>		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Palent Documents. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>2</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>2</sup>Nand of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. <sup>2</sup>Applicant is to place a check mark here if English language Translation is afteched.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, PO Box 1450. Alexandra, Virginia 2233-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450. Alexandra, Virginia 2233-1450.